19 Nov 2012 07:00
Omega Diagnostics Group PLC
("Omega" or the "Company")
Regional Selective Assistance - Grant funding
Omega, the AIM listed medical diagnostics company focussed on allergy, food intolerance and infectious disease, announces that it has been awarded a Regional Selective Assistance ("RSA") grant of up to £150,000 from Scottish Enterprise.
The RSA grant has been awarded towards the project of scaling up manufacturing facilities for the Company's new CD4 test for monitoring HIV positive patients. The facility will be located at the Company's Headquarters in Alva, Central Scotland and the grant will be payable in three instalments dependent on the attainment of employment targets and capital expenditure. The project is split into two phases; the first phase being conversion of a part of the existing premises to meet initial customer demand and a second phase to allow further scale up to meet future anticipated demand. It is expected that a first instalment of £32,000 will be received in the current financial year.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Andrew Shepherd, Chief Executive | |
Kieron Harbinson, Group Finance Director Jag Grewal, Group Sales and Marketing Director | www.omegadiagnostics.com |
Seymour Pierce Limited | Tel: 020 7107 8000 www.seymourpierce.com |
Mark Percy (Corporate Finance) David Banks / Katie Ratner (Corporate Broking) | |
Walbrook PR Limited | |
Paul McManus | Tel: 020 7933 8787 Mob: 07980 541 893 paul.mcmanus@walbrookpr.com
|
Information about RSA:
RSA is a discretionary grant scheme, administered by Scottish Enterprise, that encourages businesses to undertake investment that will directly result in the creation or safeguarding of jobs in Scotland. The amount offered is dependent on the size of business, location of the project and an assessment of how much is needed for a project go ahead.